Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare ...

In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $1.53 per share, reflecting an increase of 1430% compared to the same period last year.